Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Mariner LLC

Mariner LLC grew its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 23.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,788 shares of the biopharmaceutical company's stock after buying an additional 5,844 shares during the period. Mariner LLC's holdings in Insmed were worth $2,126,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Jennison Associates LLC boosted its stake in Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company's stock valued at $53,424,000 after acquiring an additional 4,560 shares in the last quarter. Capital CS Group LLC acquired a new position in shares of Insmed during the fourth quarter worth $586,000. Tidal Investments LLC lifted its holdings in shares of Insmed by 447.0% during the 3rd quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company's stock valued at $1,759,000 after purchasing an additional 19,696 shares during the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of Insmed by 237.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company's stock worth $4,115,000 after purchasing an additional 41,918 shares in the last quarter. Finally, abrdn plc grew its stake in Insmed by 159.5% during the 4th quarter. abrdn plc now owns 289,653 shares of the biopharmaceutical company's stock worth $19,998,000 after buying an additional 178,041 shares during the last quarter.

Insider Transactions at Insmed

In other Insmed news, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total transaction of $479,192.80. Following the transaction, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at $16,412,107.84. The trade was a 2.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares of the company's stock, valued at approximately $7,766,640. This trade represents a 48.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 471,797 shares of company stock worth $37,621,239 in the last quarter. Company insiders own 3.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on INSM. Truist Financial lifted their target price on shares of Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Guggenheim restated a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Bank of America raised their target price on Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a research report on Thursday, March 20th. Stifel Nicolaus cut their price objective on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. Finally, HC Wainwright reiterated a "buy" rating and set a $90.00 target price on shares of Insmed in a research report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $94.00.

Insmed Price Performance

INSM traded up $0.73 on Friday, reaching $69.69. 13,610,728 shares of the company's stock were exchanged, compared to its average volume of 2,306,722. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The stock has a market cap of $12.67 billion, a PE ratio of -12.47 and a beta of 1.07. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock's fifty day moving average price is $74.38 and its 200-day moving average price is $73.56.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Sell-side analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.